Somaxon Pharmaceuticals (SOMX) announced yesterday’s, after market closet, hat it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving Silenor(R) 3 mg and 6 mg tablets. The settlement agreement with Mylan grants […]